Prelude Therapeutics Incorporated (PRLD) earnings
PRLD earnings moved a median of -3.33% by the close. Quarterly and annual PRLD reports and results, each read against the price at its own news timestamp. Back to the PRLD overview →
20 measured PRLD earnings events.
Where these PRLD earnings landedvs 20 measured PRLD earnings reactions
| Middle 50% of PRLD earnings reactions | -5.36% to +6.76% |
|---|---|
| Median reaction (to close) | -3.33% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 PRLD earnings events with a measured close landed between -5.36% and +6.76%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Prelude Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -0.91% | +7.47% | |
| Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -0.91% | +7.47% | |
| Form 10-Q Prelude Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.04% | -3.33% | |
| Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.04% | -3.33% | |
| Form 10-K Prelude Therapeutics For: Dec 31 | SEC filing · Form 10-K | +5.35% | +20.40% | |
| Form 10-Q Prelude Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.72% | +6.52% | |
| Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.72% | +6.52% | |
| Form 10-Q Prelude Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -2.98% | +4.19% | |
| Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.98% | +4.19% | |
| Form 10-Q Prelude Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -6.45% | |
| Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -6.45% | |
| Form 10-K Prelude Therapeutics For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.94% | |
| Form 10-Q Prelude Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.76% | -3.79% | |
| Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.76% | -3.79% | |
| Form 10-Q Prelude Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -1.40% | -5.00% | |
| Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.40% | -5.00% | |
| Form 10-Q Prelude Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -7.50% | |
| Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | -7.50% | |
| Form 10-K Prelude Therapeutics For: Dec 31 | SEC filing · Form 10-K | +6.00% | +32.29% | |
| Form 10-Q Prelude Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +6.90% | +27.01% |
Keep exploring
More PRLD: analyst actions → · SEC filings → · PRLD overview →